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Abstract
Background: Mycobacterium tuberculosis can enter into a dormant state which has resulted in one
third of the world's population being infected with latent tuberculosis making the study of latency
and reactivation of utmost importance. M. tuberculosis encodes five resuscitation promoting factors
(Rpfs) that bear strong similarity to a lysozyme-like enzyme previously implicated in reactivation of
dormant bacteria in vitro.
We have developed an intraperitoneal infection model in mice, with immune modulation, that
models chronic infection with similar properties in mouse lungs as those observed in the murine
aerosol infection model. We have assessed the behavior of mutants that lack two or three rpf genes
in different combinations in our intraperitoneal model.
Methods: C57Bl/6 mice were intraperitonealy infected with H37Rv wild type M. tuberculosis or
mutant strains that lacked two or three rpf genes in different combinations. After 90 days of
infection aminoguanidine (AG) or anti-TNFα antibodies were administrated. Organ bacillary loads
were determined at various intervals post infection by plating serial dilutions of organ homogenates
and enumerating bacteria.
Results: We found that the rpf triple and double mutants tested were attenuated in their ability
to disseminate to mouse lungs after intraperitoneal administration and were defective in their
ability to re-grow after immunosuppression induced by administration of aminoguanidine and anti-
TNFα antibodies.
Conclusion: Rpf proteins may have a significant physiological role for development of chronic TB
infection and its reactivation in vivo.
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Background
Mycobacterium tuberculosis (MTB), the causative agent of
tuberculosis (TB) is responsible for the largest number of
deaths attributive to a single human pathogen. This exqui-
sitely adapted bacterium has infected almost a third of the
world's population [1] with approximately 8 million new
cases and several million deaths every year. The majority
of infected people carry the tubercle bacillus in a dormant
or latent form and hence display no signs of primary dis-
ease. However, these people carry a 5–10% life time risk
of developing reactivation disease and HIV positive indi-
viduals carry a >10% risk of developing tuberculosis (2 –
23% during lifetime in HIV-negative populations and 5 –
10% per year for HIV-infected populations [2]). As a result
the study of the clinically latent state and subsequent reac-
tivation has been the subject of intense investigation and
is considered as an essential part of the general strategy to
prevent the spread of TB. To this end novel specific exper-
imental models should be evaluated and applied in the
search and testing of new targets and chemical interven-
tions for the prevention and treatment of dormant forms
of TB infection.
Several in vitro and in vivo animal models have been estab-
lished in an attempt to mimic the latent state and subse-
quent reactivation disease. Detailed characterisation of
these models in recent years has contributed significantly
to our understanding of the biology of MTB [3-5]. Modern
molecular technologies (transcriptional profiling using
microarrays, proteomic analyses, and real-time quantita-
tive reverse-transcription PCR) have been employed to
characterise MTB in the various persistence models cur-
rently in use, which have revealed both similarities and
differences between them [6,7]. Some in vitro models sug-
gest that viable cells of MTB have the capacity to adopt a
non-culturable state and that culturability can be restored
by providing nutrients in the form of fresh media [4]. This
resembles the situation in vivo, in the Cornell model,
which is probably most adequate, where bacteria are able
to assume a dormant state post drug treatment and are
then able to reactivate upon generalized immune suppres-
sion [8,9] or spontaneously [10]. However, the disadvan-
tages of this model are the long time needed to complete
studies and significant variability of the results in different
animal populations [11]. The widely used murine model
of chronic TB infection is less complicated than the Cor-
nell model but its relevance to paucibacillary tuberculosis
latency in humans is questionable. With this model bac-
teria can be administered either intravenously or aerogen-
ically, with the former the results following infection in
mice are highly dependent on the infection dose (which
varies significantly in different studies), the way the inoc-
ulum is prepared, and the mouse strain. Aerogenic chal-
lenge with a low dose of bacteria provides more consistent
results [12,13]. This model permits long-term survival of
the mice with relatively high and essentially stable num-
bers of bacteria in the lungs and spleen [14]. Although less
frequently used, intra-peritoneal (IP) administration of
MTB results in a moderate and stable bacterial load in the
organs over a period of 50 weeks post-infection [15].
An understanding of the molecular mechanisms that con-
trols the transition of viable mycobacteria to a dormant
state and vice versa will be of great value for the develop-
ment of novel interesting targets and new compounds
that have activity against latent forms of tuberculosis. The
resuscitation-promoting factor (Rpf) is a member of a pro-
tein family that is found throughout the actinobacteria. In
Micrococcus luteus, the addition of Rpf (a secreted protein,
which is active at picomolar concentrations) was neces-
sary for restoration of culturability from a dormant state,
[16] furthermore Rpf also stimulated multiplication of
normal viable bacteria [17,18]. Disruption of the rpf gene
was not possible in M. luteus in the absence of a second
functional copy, strongly suggesting essentiality of this
protein for normal growth [17]. MTB contains five rpf-like
genes, whose products, RpfA-E, when expressed as recom-
binant proteins in E. coli, have similar properties to that of
M. luteus Rpf [18]. The presence of rpf-like genes in MTB
raises the possibility that their products may also control
bacterial growth and resuscitation in vivo. Unlike the M.
luteus Rpf, none of the Rpf-like proteins in MTB are indi-
vidually essential for growth in vitro or pathogenesis in
vivo [19-21]. We have shown that two different triple
mutants lacking rpfA, rpfC and either rpfD or rpfB were
defective for resuscitation in vitro however, their growth
characteristics in vitro were similar to wild type. Further-
more these triple mutants revealed significant differential
attenuation in virulence in a mouse model of semi-acute
TB infection and showed reduced ability to proliferate in
the lungs and spleens of infected mice [20]. Recently it has
been reported that deletion of Rv1009 (RpfB) results in
delayed reactivation of bacterial growth after immune
suppression in the mouse model of chronic tuberculosis
[22].
In this study we demonstrate that multiple rpf deletion
mutants revealed differential attenuation in TB chronic
model established by the intra-peritoneal route of infec-
tion and in reactivation after immunosuppression.
Methods
Bacteria, growth conditions and mouse strains
Mutant strains of MTB that lacked two or three of the rpf
genes are described previously [20]. MTB H37Rv wild type
and mutant strains were grown in Middlbrook 7H9 media
containing 0.05% Tween 80 and 10% of Growth Supple-
ment ADC (HIMEDIA) to mid-log phase and then stored
in aliquots at -70°C until further use.BMC Infectious Diseases 2007, 7:146 http://www.biomedcentral.com/1471-2334/7/146
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Mouse infections
Six to eight week old C57BL/6 female mice (supplied
from the Pushino Animal Breeding Facility) were main-
tained in animal facilities of SRCAMB in Obolensk which
is in compliance with the Standards for Humane Care and
Use of Laboratory Animals (OLAW Assurance number
A5500-01, expires on 10/31/2011). The animals were
maintained under Animal Biosafety Level 3 conditions
throughout the study in cages with filtered air and on ster-
ile water. The animal protocol employed in this study was
approved by the Institutional Animal Care and Use Com-
mittee.
Mice were infected intraperitoneally with frozen stocks of
wild type and mutant strains, using an infection dose of
ca. 103 colony forming units (CFUs) per mouse in 0.2 ml
of suspension. At various times after infection the mice
were euthanized with CO2 and portions of the lungs and
spleen were homogenized in PBS with 0.05% Tween 80.
The numbers of viable bacteria in the lungs were moni-
tored over time by plating serial dilutions of organ
homogenates from individual mice (6 animals per time
point) on to Middlebrook 7H11 (HIMEDIA) agar. For the
first time point (10 days) homogenates from different
mice were combined before plating to decrease the limit
of detection, given the very low numbers of organisms
present at this time point. The CFUs were counted after 21
days incubation at 37°C. The data were expressed as the
log10 value of the mean number of bacteria recovered
from different animals.
Aminoguanide and anti TNFα Antibody administration
Aminoguanidine carbonate (AG) (Sigma) was adminis-
tered 90 days postinfection (1 ml, 1% wt/vol) with a
stomach pump for a period of 14 days. Monoclonal anti-
bodies to TNF-α (kindly provided by Dr. Abbasova S.G.)
were administrated intraperitoneally in physiological
saline (100 µg in 0.2. ml per mouse per day for 10 days).
Histopathology
Mice lungs were fixed in 10% formaline, embedded in
paraffin, sectioned and stained with hematoxylin/eosin.
Results
IP model of chronic TB infection
Mice were infected intraperitoneally with H37Rv at an ini-
tial dose of ca. 103 CFU per mice and steady-state chronic
infection was established in both lungs and spleen as
determined by the stable bacillary load in these organs at
50 days post infection (Figure 1). Bacteria appeared first in
the spleen and then in lungs similarly with intravenous
infection of mice [20]. However, the observed kinetics of
MTB multiplication was slower and the final bacillary
loads were lower by 1–1.5 orders of magnitude) in com-
parison with published results for low dose aerogenic
infections (see refs.14,22) Administration of AG (a nitric
oxide synthase inhibitor which will result in immune sup-
pression [23]) at 90 days postinfection resulted in an
increase in CFUs and development of large granulomas in
lungs (Figure 2). Histopathologic analysis of the lungs
after AG administration revealed areas with decreasing
numbers of lymphocytes, increased infiltration of macro-
phages and overall progression of the granulomatous
response in the lungs of infected mice. Furthermore, addi-
tion of anti-TNFα antibodies resulted in similar reactiva-
tion of bacterial growth in lungs, Figure 1. To prevent the
negative side effects of long term immune suppression we
used a short-term regimen for administration of these
compounds which resulted in a transient increase in CFUs
in lungs up to two orders of magnitude above steady-state
level. This transition lasted about 2 months, after which
the CFUs decreased to the initial level for anti TNFα and
to slightly higher level for AG (Figure 1). These data
clearly show the applicability of the IP model for mode-
ling of chronic infection in mice with growth and subse-
quent stabilization of CFUs in organs over time, similarly
to aerogenic challenge.
Growth kinetics of M. tuberculosis in organs after intraperi- tonel infection of C57Bl/6 mice Figure 1
Growth kinetics of M. tuberculosis in organs after 
intraperitonel infection of C57Bl/6 mice. C57Bl/6 mice 
were infected via the intraperitoneal route with 103 CFUs 
per animal. After 90 days of infection aminoguanidine (AG) 
or anti-TNFα antibodies were administered. For details see 
Materials and Methods. Mice were sacrificed at several time 
points post infection and the organ bacillary loads were esti-
mated by plating serial dilutions of spleen and lung homoge-
nates (from 6 mice per time point) onto agar medium. Each 
infected group contained 60 mice. The curves shown repre-
sent the average of one experiment and each experiment 
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Assessment of rpf deletion mutants in the IP model of 
chronic infection
Using the model described above we examined behavior
of MTB strains which were selectively depleted of rpf genes
in different combinations. We first assessed the double
mutants which were deleted for rpfA and rpfC (KDD7)
and deleted for rpfA and rpfB (KDD6) [20]. The initial IP
infection dose was similar to the wild type and both dou-
ble mutant strains were capable of establishing chronic
infection however, the steady-state CFU levels were
slightly lower than those observed for the wild type strain,
Figure 3A and 3B. The KDD7 mutant appeared to be more
attenuated than the KDD6 mutant since the time needed
to establish chronic infection was longer for the former.
Interestingly an increase in CFUs was observed with
KDD7- albeit not as pronounced as for the wild type –
during immune suppression and this effect was not seen
with KDD6, Figure 3A and 3B. We also assessed triple rpf
deletion mutants which were depleted of three rpf genes,
rpfA ∆rpfC ∆rpfB (KDT8) and ∆rpfA ∆rpfC ∆rpfD (KDT9)
[20] in our IP model of chronic infection. Both triple rpf
deletion mutants tested are attenuated for growth in our
model and achieved lower CFUs during chronic infection
when compared to the wild type, Figure 4A and 4B with
KDT9 and KDT8 showing 7 × 103 and 80 CFUs respec-
tively at the onset of chronic infection. More time is
required to establish steady-state levels of CFU in lungs for
both triple mutants in comparison with wild type (150
days for KDT9 and 100 days for KDT8 in contrast to 60
Growth kinetics of M. tuberculosis in lungs after intraperitonel  infection of C57Bl/6 mice with double rpf deletion mutants Figure 3
Growth kinetics of M. tuberculosis in lungs after intra-
peritonel infection of C57Bl/6 mice with double rpf 
deletion mutants. Infection dose for wild type, KDD6 and 
KDD7 strains was identical (ca. 103 CFU per animal). See leg-
end to Figure 1 and Materials and Methods for details. Dot-
ted lines represent the kinetics of infection with the wild type 












































Histopathology of the lungs of intraperitonealy infected  C57Bl/6 mice before (90 days postinfection, A) and after  aminoguanidine administration (120 days postinfection, B) Figure 2
Histopathology of the lungs of intraperitonealy 
infected C57Bl/6 mice before (90 days postinfection, 
A) and after aminoguanidine administration (120 
days postinfection, B). Lungs were sectioned and stained 
with hematoxilin and eosin. Magnification, 100×.
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days for wild type). In contrast to the wild type the triple
mutants did not show a significant increase in CFUs com-
pared to untreated controls upon AG or anti TNFα anti-
body administration which in this case resulted in the
recruitment of mainly lymphocytes to sites of infection in
the lungs (not shown). Interestingly, the CFUs for KDT8
decreased during chronic infection and whilst the bacil-
lary load in mice infected with KDT9 showed a modest
increase.
Discussion
In this study we have shown that IP infection does result
in chronic TB infection in mouse lungs similar to that
observed during low dose aerosol infection. This type of
infection is not common as the natural route of TB infec-
tion is absorption of bacteria by lung tissues. The kinetics
of accumulation of bacteria in the organs after IP admin-
istration is slower than that of chronic TB via aerogenic
infection (stabilization of CFU numbers at an almost con-
stant level after 60 days vs 20–35 days for aerogenic infec-
tion) [14,22]. The advantages of this approach are low
level cross contamination between animals and low cost
of the experiments (no need a special apparatus for aero-
genic infection). Dhillon et al. have reported on establish-
ing of chronic TB infection in Balb/c mice with CFU levels
of ca 104 CFU in lungs and in spleens after 4 weeks of IP
infection but the kinetic curves were not published [24]. It
is interesting that the significant portion of cells recovered
from organs in this model [24] were non-culturable on
solid medium but capable of growth in liquid media [24].
These observations bear some similarity to dormant MTB
cells obtained in vitro [4] and are suggestive of the forma-
tion of a population of dormant (latent) bacteria in the IP
model. It is interesting to note that a similar population of
non-culturable bacteria could also be isolated when MTB
was grown in macrophages [25] Evidently, the stable
CFUs in organs at 60 days post infection are controlled in
an immune dependent fashion as with low dose aerosol
infection since immune suppression by AG or anti-TNFα
antibodies resulted in significant increase of CFU levels in
lungs after 20–30 days of drug administration. Similar
results were also observed for chronic infection induced
after aerosol challenge [22]. AG is known as an effective
inhibitor of nitric oxide synthase (NOS) and induces reac-
tivation of bacillary growth in mice with chronic TB infec-
tion [26,27]. As expected AG administration in our model
resulted in increased bacillary growth and an increase in
the lesion area in the lungs of infected mice (Figure 2).
Nitric oxide has been shown to alter the regulation of an
endothelial derived mediator of vascular tone, endothe-
lin-1 (ET-1). It was demonstrated that increasing endog-
enous NO generation through activation of NOS will lead
to a decrease in ET-1 [28]. It is possible that AG adminis-
tration can result in an increase in ET-1 possibly followed
by vasoconstriction, pulmonary hypertension and
hypoxia. These factors will result in augmentation of
lesion area in lungs as found in this study (Figure 2). In
the present study the increase in CFU is transient in con-
trast to published results [22,26]) as AG was given to mice
for a short period only (10 days). This approach makes it
possible to observe the direct response of bacterial multi-
plication to inhibition of NOS without interference by the
negative site effects caused by long-term administration of
AG. A similar reactivation effect was observed after admin-
istration of anti-TNFα antibodies. It has been previously
shown that anti-TNFα antibodies were able to induce
reactivation of TB in chronically infected mice and pro-
duced significant histopathological deterioration in
organs [27]. This effect of inactivation of TNFα is proba-
bly due to different mechanisms including modulation of
Growth kinetic of M. tuberculosis in lungs after intraperitonel  infection of C57Bl/6 mice with triple rpf deletion mutants Figure 4
Growth kinetic of M. tuberculosis in lungs after intra-
peritonel infection of C57Bl/6 mice with triple rpf 
deletion mutants. Infection dose for wild type, KDT9 and 
KDT8 strains was identical (ca. 103 CFU per animal). See leg-
end to Figure 1 and Materials and Methods for details. Dot-
ted lines represent the kinetics of infection with the wild type 
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inflammatory state of the lungs, attenuation of the expres-
sion of NOS2 in the lungs and altered expression of other
cytokines and chemokines [27,29]. The increase in CFUs
after anti-TNFα treatment in the present study was similar
to data reported in previous experiments with chronically
infected mice (ca. 1.5 log after administration) [27].
Again, due to the short regimen of antibody administra-
tion, the increase in CFUs is transient.
Generally, the IP infection model reveals features similar
to the more commonly used low dose aerogenic infection
model, such as the establishment a steady-state level of
CFUs in organs that does not change significantly over
time. Given that clinical latency in humans is character-
ized by low bacillary loads, the IP route of infection may
in fact model TB latency even better than aerogenic infec-
tion as the steady-state bacterial load in this study was
lower than for aerogenic infection for the same strain in
our studies (unpublished results and see also [14,15,30]).
In a previous study, the behavior of MTB strains that were
deleted for either one or three rpf genes were investigated
in vitro and in vivo and we found that these mutants did
not show significant growth attenuation in vitro although
the triple mutants were significantly and differentially
attenuated in B6 mice [20]. Similarly, double mutants
used in this study grew as well as the wild type in Sauton's
medium either in broth culture or on plates (data not
shown). These strains have also been checked for their
ability to resuscitate from a "non-culturable" state after
prolonged incubation in stationary phase under anaero-
bic conditions [20]. Strains deleted for one rpf gene only
showed no defects in their ability to resuscitate however,
the triple mutants were significantly defective for resusci-
tation in this model. This defect for the triple mutants
could be restored by addition of culture filtrate (taken
from log phase MTB cells) to the resuscitation medium [B.
Kana et al., in preparation] indicating that the inability of
bacteria to spontaneously resuscitate was not only due to
poor viability of the mutant strains in this model. We
tested KDD6 for its ability to recover from a non-cultura-
ble state in vitro and we found no defects (data not
shown).
In this study we show that one double (KDD7) and both
triple rpf deletion mutants reveal significant attenuation
in a chronic in vivo model after IP infection. Moreover,
deletion of three rpf genes resulted in complete arrest of
cell multiplication after immune suppression in the case
of KDT8. In our model KDD7 seems to be more attenu-
ated than KDT8 (which was derived from KDD7) at 90
days (3.5 log CFUs for KDT8 vs 2.9 log for KDD7) (Figures
3B and 4B). However, this difference is reduced as the
experiment progresses and could also be associated with
some natural variation in mice sensitivity in different
groups. Deletion of the rpfA, rpfC and rpfD genes (KDT9)
resulted in greater attenuation of MTB in the IP model
than deletion of the rpfA, rpfC and rpfB genes (KDT8) (Figs
4A,B), in contrast to previously published data that indi-
cated KDT8 was more attenuated for growth in B6 mice
than KDT9 [20]. We speculate that this discrepancy could
be related to the different models used in the published
experiment (intravenous, acute infection, B6 mice) com-
pared to the current study. It is possible that the Rpf pro-
teins could be differentially important for MTB
proliferation depending on the route of bacillary dissem-
ination. We are currently attempting to genetically com-
plement the multiple rpf deletion strains and further pair
wise experiments with complemented derivatives should
confirm unequivocally the role of Rpfs in pathogenesis.
However, our data are reflective of the notion that Rpf
proteins may have a significant physiological role under
conditions of bacterial stress in vivo. Indeed, actively
grown mycobacteria were not sensitive to Rpf [18] whilst
aged cultures or "non-culturable" cells were sensitive to
Rpf addition in form of exogenously administrated pro-
tein or the plasmid coding for Rpf synthesis [18,31]. We
also found that bacterial growth from a small inoculum in
non-optimum medium was sensitive to Rpf administra-
tion [18]. Chronic infection (low MTB initial dose) could
be considered as less permissive for mycobacterial multi-
plication in comparison with the acute infection phase
and therefore, the role of Rpf proteins in the development
of chronic TB infection and reactivation become more
prominent and it is clear that different Rpfs contribute dif-
ferently to the observed effect. It seems that RpfC is impor-
tant for bacterial dissemination in the IP model in double
knockouts while RpfD plays a more significant role in tri-
ple mutant combinations. At the same time RpfB is
important for AG induced reactivation for the double
mutants which is in accordance with the observations of
Tufariello  et al. for a single rpfB  mutant [22].
The observed behavior of the different rpf mutants in vivo
elucidates a sophisticated interplay between different Rpf
proteins during cell growth and cell recovery after dor-
mancy. Indeed, being almost redundant in single
mutants, Rpf proteins exhibited less redundancy in dou-
ble and triple mutants. We speculate that the different
Rpfs perform similar functions in the cell (e.g. cell wall
processing [32]) but at different loci of the target or with
different efficiencies. This is supported by the fact that all
Rpf molecules from MTB show differences in their varia-
ble domain which is probably important for cell wall
binding [30]. In multiple mutants it is likely, that some of
the remaining molecules could substitute for the deleted
Rpf better than others and the probability of such success-
ful substitution decreases in the order of single-double-tri-
ple mutants. Alternatively, expression of a particular rpf
gene could influence (directly or indirectly) the expres-BMC Infectious Diseases 2007, 7:146 http://www.biomedcentral.com/1471-2334/7/146
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sion of the others. Future studies should elucidate these
possibilities. Despite the fact that the mechanisms of Rpf
activity are not fully understood it is clear that these pro-
teins represent interesting targets for the design of chemi-
cal compounds against development of chronic\ latent TB
infection. If dormant MTB cells sustain some metabolic
activity, such anti-Rpf compounds could not only stop
reactivation disease but eventually kill latent organisms.
Conclusion
1. IP infection results in chronic TB infection in mouse
lungs similar to that observed during low dose aerosol
infection.
2. Rpf proteins may have a significant physiological role
for development of chronic TB infection and its reactiva-
tion in vivo.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
BK and KD carried out the molecular genetic studies,
made KO mutants, BK participated in the manuscript
drafting. SB and VP carried out IP mouse model. EG par-
ticipated in histopathology studies. ASK conceived of the
study, and participated in its design and coordination and
helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We thank Tatyana Combarova for expert technical assistance with the ani-
mal infection, Bhavna Gordhan for characterization of MTB KO strains, 
Professors Valerie Mizrahi and Alexander Apt for critical reading of the 
manuscript and very helpful discussions.
This work was supported by The Program "Molecular and Cellular Biol-
ogy", Russian Academy of Sciences and The Russian Foundation for Basic 
Research (grant 06-04-49201).
References
1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione RC: Consensus
statement. Global burden of tuberculosis – estimated inci-
dence, prevalence, and mortality by country. WHO Global
Surveillance and Monitoring Project.  JAMA 1999, 82:677-686.
2. Parrish NM, Dick JD, Bishai WD: Mechanisms of latency in Myco-
bacterium tuberculosis.  Trends Microbiol 1998, 6:107-112.
3. Wayne LG, Hayes LG: An in vitro model for sequential study of
shiftdown of Mycobacterium tuberculosis through 2 stages of
nonreplicating persistence.  Infect Immun 1996, 64:2062-2069.
4. Shleeva MO, Bagramyan K, Telkov MV, Mukamolova GV, Young M,
Kell DB, Kaprelyants AS: Formation and resuscitation of "non-
culturable" cells of Rhodococcus rhodochrous and Mycobacte-
rium tuberculosis in prolonged stationary phase.  Microbiology
2002, 148:1581-1591.
5. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuer-
mberger EL, Grosset J, Bishai WR: Dormancy phenotype dis-
played by extracellular Mycobacterium tuberculosis within
artificial granulomas in mice.  J Exp Med 2004, 200:647-657.
6. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM,
Sherman DR, Schoolnik GK: Inhibition of respiration by nitric
oxide induces a Mycobacterium tuberculosis dormancy pro-
gram.  J Exp Med 2003, 198:705-713.
7. Voskuil MI, Visconti KC, Schoolnik GK: Mycobacterium tuberculo-
sis gene expression during adaptation to stationary phase
and low-oxygen dormancy.  Tuberculosis (Edinb) 2004, 84:218-27.
8. McCune RM, Feldmann FM, Lambert HP, McDermott W: Microbial
persistence. I. The capacity of tubercle bacilli to survive ster-
ilization in mouse tissues.  J Exp Med 1966, 123:445-468.
9. McCune RM, Feldmann FM, McDermott W: Microbial persistence.
II. Characteristics of the sterile state of tubercle bacilli.  J Exp
Med 1966, 123:469-486.
10. Radaeva TV, Nikonenko BV, Mischenko VV, Averbakh MM Jr, Apt AS:
Direct comparison of low-dose and Cornell-like models of
chronic and reactivation tuberculosis in genetically suscepti-
ble I/St and resistant B6 mice.  Tuberculosis 2005, 85:65-72.
11. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, Flynn JL: Reactiva-
tion of latent tuberculosis: variations on the Cornell murine
model.  Infect Immun 1999, 67:4531-38.
12. Orme IM, Collins FM: Mouse model of tuberculosis.  In Tubercu-
losis: pathogenesis, protection, and control Edited by: Bloom BR. ASM
Press, Washington; 1994:113-134. 
13. Rhoades ER, Frank AA, Orme IM: Progression of chronic pulmo-
nary tuberculosis in mice aerogenically infected with virulent
Mycobacterium tuberculosis.  Tuber Lung Dis 1997, 78:57-66.
14. Dahl JL, Kraus CN, Boshoff HI, Doan B, Foley K, Avarbock D, Kaplan
G, Mizrahi V, Rubin H, Barry CE: The role of RelMtb-mediated
adaptation to stationary phase in long-term persistence of
Mycobacterium tuberculosis in mice.  Proc Natl Acad Sci U S A
2003, 100:10026-31.
15. Phyu S, Mustafa T, Hofstad T, Nilsen R, Fosse R, Bjune G: A mouse
model for latent tuberculosis.  Scandinavian Journal of Infectious
Diseases 1998, 30:59-68.
16. Mukamolova GV, Kaprelyants AS, Young DI, Young M, Kell DB: A
bacterial cytokine.  Proc Natl Acad Sci USA 1998, 95:8916-8921.
17. Mukamolova GV, Turapov OA, Kazaryan K, Telkov M, Kaprelyants
AS, Kell DB, Young M: The  rpf  gene of Micrococcus luteus
encodes an essential secreted growth factor.  Mol Microbiol
2002, 46:611-621.
18. Mukamolova GV, Turapov OA, Young DI, Kaprelyants AS, Kell DB,
Young M: A family of autocrine growth factors in Mycobacte-
rium tuberculosis.  Mol Microbiol 2002, 46:623-635.
19. Downing KJ, Betts JC, Young DI, McAdam RA, Kelly F, Young M, Miz-
rahi V: Global expression profiling of strains harbouring null
mutations reveals that the five rpf-like genes of Mycobacte-
rium tuberculosis show functional redundancy.  Tuberculosis
2004, 84:167-179.
20. Downing KJ, Mischenko VV, Shleeva MO, Young DI, Young M,
Kaprelyants AS, Apt AS, Mizrahi V: Mutants of Mycobacterium
tuberculosis lacking three of the five rpf-like genes are defec-
tive for growth in vivo and for resuscitation in vitro.  Infection
and Immunity 2005, 73:3038-3043.
21. Tufariello JM, Jacobs WR, Chan J: Individual  Mycobacterium
tuberculosis resuscitation-promoting factor homologues are
dispensable for growth in vitro and in vivo.  Infect Immun 2004,
72:515-526.
22. Tufariello JM, Mi K, Xu J, Manabe YC, Kesavan AK, Drumm J, Tanaka
K, Jacobs WR Jr, Chan J: Deletion of the Mycobacterium tuber-
culosis resuscitation-promoting factor Rv1009 gene results
in delayed reactivation from chronic tuberculosis.  Infect
Immun 2006, 74:2985-2995.
23. Flynn JL, Scanga CA, Tanaka KE, Chan J: Effects of aminoguanidine
on latent murine tuberculosis.  J Immunol 1998,
160(4):1796-1803.
24. Dhillon JL, Lowrie D, Mitchison DA: Mycobacterium tuberculosis
from chronic murine infections that grows in liquid but not
on solid medium.  BMC Infect Dis 2004, 4:51.
25. Biketov SF, Mukamolova GV, Potapov V, Gilenkov E, Vostroknutova
G, Kell DB, Young M, Kaprelyants AS: Culturability of Mycobacte-
rium tuberculosis cells isolated from murine macrophages: a
bacterial growth factor promotes recovery.  FEMS Immunol
Med Microbiol 2000, 29:233-240.
26. Botha T, Ryffel B: Reactivation of latent tuberculosis by an
inhibitor of inducible nitric oxide synthase in an aerosol
murine model.  Immunology 2002, 107:350-7.
27. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, Tsai MM,
Flynn JL, Chan J: Effects of tumor necrosis factor alpha on hostPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2007, 7:146 http://www.biomedcentral.com/1471-2334/7/146
Page 8 of 8
(page number not for citation purposes)
immune response in chronic persistent tuberculosis: possi-
ble role for limiting pathology.  Infect Immun 2001, 69:1847-55.
28. Kelly Lisa K, Wedgwood Stephen, Steinhorn Robin H, Black Stephen
M: Nitric oxide decreases endothelin-1 secretion through the
activation of soluble guanylate cyclase.  Am J Physiol Lung Cell Mol
Physiol 2004, 286:L984-L991.
29. Gordon S: Alternative activation of macrophages.  Nat Rev
Immunol 2003, 3:23-35.
30. Senaratne R, De Silva D, Williams S, Mougous J, Reader R, Zhang T,
Chan S, Sidders B, Lee D, Chan J, Bertozzi C, Riley L: 5'-Adenos-
inephosphosulphate reductase (CysH) protects Mycobacte-
rium tuberculosis against free radicals during chronic
infection phase in mice.  Molecular Microbiology 2006,
59:1744-1753.
31. Shleeva MO, Mukamolova GV, Young M, Williams HD, Kaprelyants
AS:  Formation of "non-culturable" cells of Mycobacterium
smegmatis in stationary phase in response to growth under
sub-optimal conditions and their Rpf-mediated resuscita-
tion.  Microbiology 2004, 150:1687-1697.
32. Mukamolova GV, Murzin AG, Salina EG, Demina GR, Kell DB,
Kaprelyants AS, Young M: Muralytic activity of Micrococcus
luteus Rpf and its relationship to physiological activity in pro-
moting bacterial growth and resuscitation.  Molecular Microbiol-
ogy 2006, 59:84-98.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/7/146/pre
pub